The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Transthyretin Amyloidosis (ATTR) Market Research Report 2025
Synopsis
Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).
The global Transthyretin Amyloidosis (ATTR) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
United States accounts for highest ATTR Amyloidosis Cases, followed by EU5 (Italy, France, Spain, Germany, UK) and Japan.
This report aims to provide a comprehensive presentation of the global market for Transthyretin Amyloidosis (ATTR), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin Amyloidosis (ATTR).
Report Scope
The Transthyretin Amyloidosis (ATTR) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Transthyretin Amyloidosis (ATTR) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Transthyretin Amyloidosis (ATTR) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Segment by Type
Hereditary ATTR (HATTR)
Wild-Type (WT) ATTR
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Transthyretin Amyloidosis (ATTR) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point mutations within TTR allele, wild-type ATTR is caused by the misfolding of Wild-Type TTR. Major prevalence of Hereditary ATTR is observed in the 7MM, and this type has been further sub-classified into Familial Amyloidosis Polyneuropathy (FAP) and Familial Amyloidosis Cardiomyopathy (FAC).
The global Transthyretin Amyloidosis (ATTR) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
United States accounts for highest ATTR Amyloidosis Cases, followed by EU5 (Italy, France, Spain, Germany, UK) and Japan.
This report aims to provide a comprehensive presentation of the global market for Transthyretin Amyloidosis (ATTR), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin Amyloidosis (ATTR).
Report Scope
The Transthyretin Amyloidosis (ATTR) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Transthyretin Amyloidosis (ATTR) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Transthyretin Amyloidosis (ATTR) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Alnylam Pharmaceuticals
Ionis Pharmaceuticals
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Segment by Type
Hereditary ATTR (HATTR)
Wild-Type (WT) ATTR
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Transthyretin Amyloidosis (ATTR) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transthyretin Amyloidosis (ATTR) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Hereditary ATTR (HATTR)
1.2.3 Wild-Type (WT) ATTR
1.3 Market by Application
1.3.1 Global Transthyretin Amyloidosis (ATTR) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Transthyretin Amyloidosis (ATTR) Market Perspective (2019-2030)
2.2 Transthyretin Amyloidosis (ATTR) Growth Trends by Region
2.2.1 Global Transthyretin Amyloidosis (ATTR) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Transthyretin Amyloidosis (ATTR) Historic Market Size by Region (2019-2024)
2.2.3 Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Region (2025-2030)
2.3 Transthyretin Amyloidosis (ATTR) Market Dynamics
2.3.1 Transthyretin Amyloidosis (ATTR) Industry Trends
2.3.2 Transthyretin Amyloidosis (ATTR) Market Drivers
2.3.3 Transthyretin Amyloidosis (ATTR) Market Challenges
2.3.4 Transthyretin Amyloidosis (ATTR) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transthyretin Amyloidosis (ATTR) Players by Revenue
3.1.1 Global Top Transthyretin Amyloidosis (ATTR) Players by Revenue (2019-2024)
3.1.2 Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Players (2019-2024)
3.2 Global Transthyretin Amyloidosis (ATTR) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Transthyretin Amyloidosis (ATTR) Revenue
3.4 Global Transthyretin Amyloidosis (ATTR) Market Concentration Ratio
3.4.1 Global Transthyretin Amyloidosis (ATTR) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transthyretin Amyloidosis (ATTR) Revenue in 2023
3.5 Transthyretin Amyloidosis (ATTR) Key Players Head office and Area Served
3.6 Key Players Transthyretin Amyloidosis (ATTR) Product Solution and Service
3.7 Date of Enter into Transthyretin Amyloidosis (ATTR) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Transthyretin Amyloidosis (ATTR) Breakdown Data by Type
4.1 Global Transthyretin Amyloidosis (ATTR) Historic Market Size by Type (2019-2024)
4.2 Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Type (2025-2030)
5 Transthyretin Amyloidosis (ATTR) Breakdown Data by Application
5.1 Global Transthyretin Amyloidosis (ATTR) Historic Market Size by Application (2019-2024)
5.2 Global Transthyretin Amyloidosis (ATTR) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Transthyretin Amyloidosis (ATTR) Market Size (2019-2030)
6.2 North America Transthyretin Amyloidosis (ATTR) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2019-2024)
6.4 North America Transthyretin Amyloidosis (ATTR) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Transthyretin Amyloidosis (ATTR) Market Size (2019-2030)
7.2 Europe Transthyretin Amyloidosis (ATTR) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2019-2024)
7.4 Europe Transthyretin Amyloidosis (ATTR) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size (2019-2030)
8.2 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2019-2024)
8.4 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Transthyretin Amyloidosis (ATTR) Market Size (2019-2030)
9.2 Latin America Transthyretin Amyloidosis (ATTR) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2019-2024)
9.4 Latin America Transthyretin Amyloidosis (ATTR) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size (2019-2030)
10.2 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2019-2024)
10.4 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Transthyretin Amyloidosis (ATTR) Introduction
11.1.4 Pfizer Revenue in Transthyretin Amyloidosis (ATTR) Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Alnylam Pharmaceuticals
11.2.1 Alnylam Pharmaceuticals Company Detail
11.2.2 Alnylam Pharmaceuticals Business Overview
11.2.3 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Introduction
11.2.4 Alnylam Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2019-2024)
11.2.5 Alnylam Pharmaceuticals Recent Development
11.3 Ionis Pharmaceuticals
11.3.1 Ionis Pharmaceuticals Company Detail
11.3.2 Ionis Pharmaceuticals Business Overview
11.3.3 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Introduction
11.3.4 Ionis Pharmaceuticals Revenue in Transthyretin Amyloidosis (ATTR) Business (2019-2024)
11.3.5 Ionis Pharmaceuticals Recent Development
11.4 Corino Therapeutics
11.4.1 Corino Therapeutics Company Detail
11.4.2 Corino Therapeutics Business Overview
11.4.3 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Introduction
11.4.4 Corino Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2019-2024)
11.4.5 Corino Therapeutics Recent Development
11.5 Proclara Bioscience
11.5.1 Proclara Bioscience Company Detail
11.5.2 Proclara Bioscience Business Overview
11.5.3 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Introduction
11.5.4 Proclara Bioscience Revenue in Transthyretin Amyloidosis (ATTR) Business (2019-2024)
11.5.5 Proclara Bioscience Recent Development
11.6 Arcturus Therapeutics
11.6.1 Arcturus Therapeutics Company Detail
11.6.2 Arcturus Therapeutics Business Overview
11.6.3 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Introduction
11.6.4 Arcturus Therapeutics Revenue in Transthyretin Amyloidosis (ATTR) Business (2019-2024)
11.6.5 Arcturus Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
